| Ablation |
| Acute myeloid leukaemia |
| Adaptive immune system |
| Allogeneic stem cell transplantation |
| Alopecia |
| Alternative treatment |
| Anaphylactoid |
| Antibody |
| Anti-CD20 |
| Antiemetic |
| Antihistamine |
| Antipyretic |
| Apoptosis |
| Astrocyte |
| Asymptomatic |
| Ataxia |
| Atrophy |
| Autoimmune disease |
| Autologous haematopoietic stem cell transplantation |
| Autoreactive |
| Axon |
| B cell |
| Bradycardia |
| Brain reserve |
| Brainstem |
| Cancer signal |
| Capillary leak syndrome |
| Cardiotoxicity |
| Central nervous system |
| Cerebellar |
| Cerebellum |
| Cerebral cortex |
| Cerebrospinal fluid |
| Clinically isolated syndrome |
| Cognitive reserve |
| Comorbidities |
| Complementary treatment |
| Compounded |
| Conditioning regimen |
| Confidence intervals |
| Contraindication |
| Cytokine |
| Cytokine-release syndrome |
| Demyelinate |
| Demyelinated |
| Demyelination |
| Dephosphorylate |
| De-risk |
| Disease-modifying treatments |
| Dose titration |
| Dysgeusia |
| Dyspepsia |
| Ejection fraction |
| Electrocardiogram |
| Eloquent |
| Encephalitis |
| Endogenous |
| End-organ |
| Enhancing lesions |
| Evoked potential |
| Expanded Disability Status Scale |
| Extended interval dosing |
| Extravasation |
| First-line therapy |
| Focal |
| Glial cells |
| Glomerulonephritis |
| GnRH agonist |
| Granule cell |
| Grey matter |
| Haematopoietic stem-cell transplantation |
| Haemolytic–uraemic syndrome |
| Half-life |
| Holistic management |
| Hyperemesis gravidarum |
| Immune reconstitution therapy |
| Immune surveillance |
| Immunocompetent |
| Immunocompromised |
| Immunoglobulin |
| Immunomodulatory |
| Immunosenescence |
| Immunosuppression |
| Immunosuppressive |
| Infectious mononucleosis |
| Inflammatory mediators |
| Innate immune system |
| Ion channel |
| JC virus-seronegative |
| JC virus-seropositive |
| JCV-seronegative |
| JCV-seropositive |
| Lesion |
| Leukocytes |
| Leukopenia |
| Lhermitte’s sign |
| Lipoatrophy |
| Listeria |
| Listeria monocytogenes |
| Listeriosis |
| Lymphocytes |
| Lymphopaenia |
| Lysis |
| Magnetic resonance imaging |
| Marginating cells |
| Medical gaslighting |
| Monoclonal gammopathy |
| Monophasic |
| MS neurologist |
| Mucositis |
| MUGA scan |
| Myelin |
| Myelination |
| Myeloablative |
| Necrosis |
| NEDA-3 |
| Network analyses |
| Neurodegenerative |
| Neurofilament |
| Neurofilament light |
| Neurological reserve |
| Neurologist |
| Neuronal transection |
| Neuropathy |
| Neuroprotective |
| Neurotropic |
| Neutralising antibodies |
| Neutropenia |
| Nocardia |
| Nocardiosis |
| Non-myeloablative |
| Off-label |
| Off-target side effects |
| Oligoclonal band |
| Oligodendrocyte |
| Oligospermia |
| Opportunistic infections |
| Optic nerve |
| Optic neuritis |
| Orphan disease |
| Parenteral |
| Phagocytosis |
| Pharmacogenomics |
| Plasma exchange |
| Platelets |
| Platform therapy |
| Positive symptom |
| Posterior fossa |
| Posterior reversible encephalopathy syndrome |
| Primary progressive MS |
| Prodrug |
| Prognosis |
| Progressive multifocal leukoencephalopathy |
| Progressive relapsing MS |
| Pseudolymphoma |
| Pyrexia |
| Radiologically isolated syndrome |
| Rebaseline |
| Relapse |
| Relapsing–remitting MS |
| Remyelinated |
| S1P modulators |
| Secondary progressive MS |
| Second-line therapy |
| Serology |
| Seronegative |
| Seropositive |
| Serum |
| Single-attack progressive MS |
| Subclinical |
| Subcutaneous |
| T cell |
| T1 gadolinium-enhancing lesions |
| T2 |
| T2 lesions |
| Tachycardia |
| Teratogenic |
| Thrombotic thrombocytopenic purpura |
| Uhtoff’s phenomenon |
| VLA-4 |
| White blood cell |
